Catalyst Pharmaceuticals (CPRX) Raised to Buy at ValuEngine

ValuEngine upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a buy rating in a research report released on Monday morning.

Several other research analysts have also recently commented on the stock. BidaskClub cut shares of Catalyst Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, March 16th. HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Catalyst Pharmaceuticals presently has an average rating of Hold and an average price target of $6.25.

Shares of NASDAQ:CPRX remained flat at $$3.34 during trading on Monday. 2,903 shares of the company were exchanged, compared to its average volume of 702,645. Catalyst Pharmaceuticals has a twelve month low of $3.33 and a twelve month high of $3.46. The company has a market cap of $342.67 million, a P/E ratio of -15.81 and a beta of 1.52.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). analysts anticipate that Catalyst Pharmaceuticals will post -0.34 earnings per share for the current year.

In other news, insider Patrick J. Mcenany bought 20,000 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The stock was purchased at an average price of $2.29 per share, for a total transaction of $45,800.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 9.60% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC grew its position in Catalyst Pharmaceuticals by 132.2% in the 4th quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 15,178 shares during the last quarter. Tanaka Capital Management Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 6.4% in the fourth quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock valued at $1,003,000 after acquiring an additional 15,515 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Catalyst Pharmaceuticals by 18.2% in the first quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 20,484 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 24,200 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 23.6% in the first quarter. Alps Advisors Inc. now owns 137,441 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 26,262 shares in the last quarter. Hedge funds and other institutional investors own 55.30% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. The company was founded by McEnany J.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply